Merck's Keytruda therapy with chemotherapy failed Phase 3 trial for high-risk endometrial cancer disease-free survival.

Merck's Keytruda therapy in combination with chemotherapy failed to meet the main goal of disease-free survival in high-risk endometrial cancer patients after surgery in a Phase 3 trial. The study's other main goal of overall survival was not formally tested due to the trial's failure. Endometrial cancer begins in the uterus's inner lining and is the most common form affecting the organ.

May 09, 2024
5 Articles

Further Reading